AUS
NZ
UK
CA
USA
IND
CSL Ltd (ASX:CSL), a major player in the ASX healthcare sector, has drawn attention with its recently announced FY24 financial results. The biotherapeutics giant operates across various segments, including vaccines and biotherapies, showcasing solid performance and growth.
For the fiscal year ending 30 June 2024, CSL reported a robust financial performance:
- Revenue: Up 11% to $14.8 billion, when adjusted for constant currency.
- Net Profit After Tax (NPATA): Increased by 11% to $2.91 billion.
- Reported Net Profit: Rose by 20% to $2.64 billion, and up 25% in constant currency terms.
- Dividends: The final dividend declared is US$1.45 per share, with a total annual dividend of US$2.64 per share, reflecting a 12% increase. In AUD terms, this translates to a 10% rise to A$4.00 per share.
Revenue from CSL Behring, the company's largest segment, saw impressive growth. The immunoglobulins portfolio, which is a significant part of this segment, experienced a 20% increase in sales, driven by high patient demand and recovery in gross margins. Additionally, albumin sales grew by 12% to $1.2 billion, haemophilia product sales increased by 10% to $1.3 billion, and specialty products sales rose by 6% to $1.94 billion.
The CSL Seqirus vaccine division also demonstrated resilience, outperforming market expectations despite a challenging environment. The growth was notably driven by the adjuvanted influenza vaccine, FLUAD.
CSL's strategic focus on innovation and efficiency is evident in its operations. The company has made significant progress in plasma collection, with reduced costs and advancements in its digital transformation efforts. The rollout of the RIKA plasmapheresis device is on track for completion by the end of FY25, promising further improvements in plasma manufacturing.
CSL Vifor continues to expand its iron volume in Europe, even with the presence of generic alternatives. The company remains optimistic about driving long-term value from this segment.
Dr. Paul McKenzie, CSL’s CEO and Managing Director, expressed satisfaction with the company's FY24 performance. He highlighted that the results align with the strategic goals communicated at the Capital Markets Day and reaffirmed confidence in maintaining double-digit earnings growth in the medium term.
Looking ahead to FY25, CSL anticipates revenue growth of approximately 5% to 7% over FY24, based on current exchange rates. NPATA is projected to be between $3.2 billion and $3.3 billion, representing growth of 10% to 13%.
The company continues to invest heavily in research and development, with FY24 R&D expenditure increasing by 12% to $1.4 billion. This commitment to innovation supports the potential for sustained growth, particularly in CSL Behring's transformational gene therapy product for haemophilia B patients, HEMGENIX.
CSL Ltd (ASX:CSL) has demonstrated strong financial health and a positive outlook, with promising prospects for continued growth and innovation in the coming year.
